Medicaments: containing alkaloids or their derivatives, containing ephedrine or its salts, for therapeutic or prophylactic uses, (not packaged for retail sale)

In 2024, medicaments: containing alkaloids or their derivatives, containing ephedrine or its salts, for therapeutic or prophylactic uses, (not packaged for retail sale) trade exhibited modest growth, with global flows reaching $60,753,517 and a three-year compound annual growth rate of +16.9% (five-year: +16.3%). The all-time peak of $60,753,517 was recorded in 2024.

Over the 30-year observation window (1995–2024), 55% of years recorded positive growth, indicating a mildly upward trajectory with periodic contractions. Trend momentum is steady (+0.0% acceleration).

The supply side is concentrated (Herfindahl-Hirschman Index 0.894). The three largest exporters — China ($58.3M), Ireland ($4.7M), and United States ($2.9M) — collectively dominate supply flows. The leading exporter has grown at +17.2% over the last three years.

On the demand side, importer concentration is concentrated (HHI 0.894). The three largest import markets are Japan ($57.4M), United States ($1.5M), and Iraq ($779.3K). The largest importing market sources from 1 different supplying countries.

The dominant trade corridor is China → Japan at $57.4M, representing 100.0% of the importer's total demand.

The volatility score for medicaments: containing alkaloids or their derivatives, containing ephedrine or its salts, for therapeutic or prophylactic uses, (not packaged for retail sale) is 27 out of 100, classified as low. Trade flows are relatively stable compared to other HS6 products, suggesting mature supply chains and predictable demand.

For market entrants, modest but steady demand provides a reasonable entry window. The concentrated supply structure suggests high barriers but also potential opportunity if dominant suppliers face disruption or capacity constraints.

Data confidence is rated "High" based on reporting coverage and consistency across OECD member and partner countries.